Last Price$12.19NASDAQ Previous Close - Last Trade as of 4:00PM ET 9/16/19
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$11.70 (5)
Ask (Size)$12.88 (20)
Day Low / HighN/A - N/A
Volume953.0 K

View Biotechnology IndustryPeer Comparison as of 09/16/2019


Epizyme Inc ( NASDAQ )

Price: $12.19
Change: +0.23 (1.92%)
Volume: 953.0 K
4:00PM ET 9/16/2019

Intrexon Corp ( NASDAQ )

Price: $6.86
Change: +0.02 (0.29%)
Volume: 5.6 K
4:00PM ET 9/16/2019

Cara Therapeutics Inc ( NASDAQ )

Price: $23.71
Change: +0.41 (1.76%)
Volume: 606.3 K
4:00PM ET 9/16/2019

Spectrum Pharmaceuticals Inc ( NASDAQ )

Price: $9.70
Change: +0.84 (9.48%)
Volume: 1.4 M
4:00PM ET 9/16/2019

NGM Biopharmaceuticals Inc ( NASDAQ )

Price: $15.73
Change: -0.13 (0.82%)
Volume: 41.9 K
4:00PM ET 9/16/2019

Read more news Recent News

Epizyme Widens Q2 Loss, Revenues Decline YoY
7:15AM ET 8/09/2019 MT Newswires

Epizyme (EPZM), a biopharmaceutical company, reported Friday Q2 net loss of $0.53 per share compared with the $0.42 loss per share in the prior year period...

Epizyme Names Tombesi as CFO
1:13PM ET 7/22/2019 MT Newswires

Epizyme (EPZM) said on Monday it has appointed Paolo Tombesi, former finance head at Insmed, as its CFO starting next month. Epizmye said that Tombesi...

Insider Trends: Insider Prolongs Selling Trend at Epizyme
7:07PM ET 6/28/2019 MT Newswires

David M Mott, Director, on Jun 27, 2019, sold 52,473 shares in Epizyme (EPZM) for $652,134. Mott, following the transactions delineated in the Form 4 SEC...

Epizyme Reports Positive Interim Data From Trial of Lymphoma Drug
9:06AM ET 6/21/2019 MT Newswires

Epizyme (EPZM) on Friday reported positive interim data from an ongoing phase 2 trial of the company's lead candidate, tazemetostat, as a monotherapy for...

Company Profile

Business DescriptionEpizyme, Inc. is a clinical-stage biopharmaceutical company, which engage in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. It also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. View company web site for more details
Address400 Technology Square
Cambridge, Massachusetts 02139
Number of Employees124
Recent SEC Filing09/11/20194/A
President, Chief Executive Officer & DirectorRobert B. Bazemore
Chief Financial OfficerPaolo Tombesi
Chief Medical OfficerShefali Agarwal
Vice President-Business DevelopmentMichael Boretti

Company Highlights

Price Open$11.88
Previous Close$12.19
52 Week Range$5.14 - 16.59
Market Capitalization$1.1 B
Shares Outstanding91.0 M
SectorHealth Technology
Next Earnings Announcement11/01/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.75
Beta vs. S&P 500N/A
Revenue$21.7 M
Net Profit Margin-588.48%
Return on Equity-50.32%

Analyst Ratings as of 09/05/2019

Consensus RecommendationConsensus Icon
Powered by Factset